β-Lactam antimicrobials: what have you done for me lately? (Q38076453)

28 August 2017

1 reference

title

β-Lactam antimicrobials: what have you done for me lately? (English)

1 reference

28 August 2017

George H Talbot

1

1 reference

PubMed ID

23346858

28 August 2017

language of work or name

English

0 references

publication date

29 November 2012

1 reference

Annals of the New York Academy of Sciences

28 August 2017

1 reference

28 August 2017

1277

1 reference

28 August 2017

76-83

1 reference

The perpetual challenge of infectious diseases.

28 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Has the era of untreatable infections arrived?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Antibiotic-resistant bugs in the 21st century--a clinical super-challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Hospital-acquired infections due to gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Three decades of beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Ceftriaxone-resistant Neisseria gonorrhoeae, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

A functional classification scheme for beta-lactamases and its correlation with molecular structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

21 January 2018

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Updated functional classification of beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

The CTX-M beta-lactamase pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

CTX-M Enzymes: Origin and Diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Identification of CTX-M β-lactamases among Escherichia coli from the community in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Wild coastline birds as reservoirs of broad-spectrum-β-lactamase-producing Enterobacteriaceae in Miami Beach, Florida

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Molecular characterization of resistance to extended-spectrum cephalosporins in clinical Escherichia coli isolates from companion animals in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Molecular characterization of extended-spectrum-β-lactamase-producing and plasmid-mediated AmpC β-lactamase-producing Escherichia coli isolated from stray dogs in South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Metallo-β-lactamases: a last frontier for β-lactams?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Current and novel antibiotics against resistant Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Antibiotics in the clinical pipeline in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Will new antimicrobials overcome resistance among Gram-negatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

In vitro and in vivo properties of BAL30376, a β-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06809.X

10.1111/J.1749-6632.2012.06809.X

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23346858